

Argyris Symeonidis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4160317/publications.pdf>

Version: 2024-02-01

245
papers

7,041
citations

81839

39
h-index

66879

78
g-index

253
all docs

253
docs citations

253
times ranked

7202
citing authors

#	ARTICLE	IF	CITATIONS
1	Bone marrow ribonucleotide reductase mRNA levels and methylation status as prognostic factors in patients with myelodysplastic syndrome treated with 5-Azacytidine. <i>Leukemia and Lymphoma</i> , 2022, 63, 729-737.	0.6	2
2	Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial. <i>American Journal of Hematology</i> , 2022, 97, 481-490.	2.0	6
3	Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. <i>Lancet Haematology</i> , 2022, 9, e98-e110.	2.2	32
4	Chronic Neutrophilic Leukemia: A Comprehensive Review of Clinical Characteristics, Genetic Landscape and Management. <i>Frontiers in Oncology</i> , 2022, 12, 891961.	1.3	9
5	Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma. <i>In Vivo</i> , 2022, 36, 1302-1315.	0.6	2
6	Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study â€œREBUILDâ€œ. <i>Cancers</i> , 2022, 14, 2768.	1.7	6
7	Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML. <i>Blood Advances</i> , 2022, 6, 5132-5145.	2.5	43
8	Upregulated hypoxia inducible factor 1 α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5-azacytidine data from the Hellenic myelodysplastic syndrome study group. <i>Hematological Oncology</i> , 2021, 39, 231-242.	0.8	1
9	SARS-CoV-2 persistence and non-protective immunity in infected haematological patients. <i>British Journal of Haematology</i> , 2021, 192, e51-e54.	1.2	4
10	The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes. <i>British Journal of Haematology</i> , 2021, 192, 978-987.	1.2	4
11	Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome. <i>Leukemia</i> , 2021, 35, 1745-1750.	3.3	15
12	A multicenter cross-sectional study of the quality of life and iron chelation treatment satisfaction of patients with transfusion-dependent β^2 -thalassemia, in routine care settings in Western Greece. <i>Quality of Life Research</i> , 2021, 30, 467-477.	1.5	4
13	Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. <i>Lancet Haematology</i> , 2021, 8, e135-e148.	2.2	32
14	Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes. <i>Blood Cancer Journal</i> , 2021, 11, 30.	2.8	2
15	Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies. <i>Annals of Hematology</i> , 2021, 100, 2279-2292.	0.8	10
16	Rare lobular capillary hemangioma associated with azacitidine in high-risk myelodysplastic syndrome patient. <i>Dermatologic Therapy</i> , 2021, 34, e14884.	0.8	1
17	The Lipoprotein Transport System in the Pathogenesis of Multiple Myeloma: Advances and Challenges. <i>Frontiers in Oncology</i> , 2021, 11, 638288.	1.3	8
18	Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World â€œPOWERFULâ€œ Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1509.	1.0	2

#	ARTICLE	IF	CITATIONS
19	Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP. <i>Oncologist</i> , 2021, 26, 597-609.	1.9	15
20	Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2021, 22, 801-812.	5.1	162
21	A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS. <i>Blood Advances</i> , 2021, 5, 3066-3075.	2.5	12
22	TACI Mutations in Primary Antibody Deficiencies: A Nationwide Study in Greece. <i>Medicina (Lithuania)</i> , 2021, 57, 827.	0.8	6
23	Subdiaphragmatic extranodal localizations at diagnosis of primary mediastinal large B-cell lymphoma: an impressive, rare presentation with no independent effect on prognosis. <i>Leukemia Research</i> , 2021, 107, 106595.	0.4	3
24	Core Set of Patient-Reported Outcomes for Myelodysplastic Syndromes - EUMDS Delphi Study in Patients and Hematologists. <i>Blood Advances</i> , 2021, , .	2.5	6
25	Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study. <i>Blood</i> , 2021, 138, 2747-2747.	0.6	1
26	Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes. <i>Haematologica</i> , 2020, 105, 632-639.	1.7	35
27	Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacytidine: Results From the Hellenic 5-Azacytidine Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 114-121.	0.2	5
28	Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry. <i>Haematologica</i> , 2020, 105, 640-651.	1.7	32
29	Effectiveness of 5-Azacytidine in older patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia: A retrospective analysis of the Hellenic (Greek) MDS Study Group. <i>Journal of Geriatric Oncology</i> , 2020, 11, 121-124.	0.5	5
30	LRF/ZBTB7A conservation accentuates its potential as a therapeutic target for the hematopoietic disorders. <i>Gene</i> , 2020, 760, 145020.	1.0	2
31	Guideline-based indicators for adult patients with myelodysplastic syndromes. <i>Blood Advances</i> , 2020, 4, 4029-4044.	2.5	12
32	Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072096612.	1.1	9
33	Development of a core outcome set for myelodysplastic syndromes " a Delphi study from the EUMDS Registry Group. <i>British Journal of Haematology</i> , 2020, 191, 405-417.	1.2	10
34	Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes. <i>Hematological Oncology</i> , 2020, 38, 541-553.	0.8	3
35	Predictors of mortality for KPC-producing <i>Klebsiella pneumoniae</i> bloodstream infections in adult neutropenic patients with haematological malignancies. <i>Infectious Diseases</i> , 2020, 52, 446-449.	1.4	2
36	Risk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes: A nationwide, registry-based cohort study. <i>EJHaem</i> , 2020, 1, 255-261.	0.4	2

#	ARTICLE	IF	CITATIONS
37	Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 5-6.	0.6	41
38	Efficacy of Interferon A-2b Monotherapy in β -Thalassemics with Chronic Hepatitis C. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 24, 189-196.	0.5	4
39	Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective. <i>Haematologica</i> , 2020, 105, 2516-2523.	1.7	12
40	Choroidal Thickness Evaluation in a Transfusion-Dependent Beta-Thalassemia Greek Population. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 4511-4518.	0.9	2
41	Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare Study. <i>Blood</i> , 2020, 136, 48-49.	0.6	7
42	Efficacy and Tolerability of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Preliminary Results of the Phase 2 Daria Study. <i>Blood</i> , 2020, 136, 19-20.	0.6	0
43	Efficacy of Daratumumab Monotherapy on Bone Metabolism of Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results from the Phase 2 Rebuild Study. <i>Blood</i> , 2020, 136, 29-29.	0.6	0
44	Mutation Profiles Identify Distinct Clusters of Lower Risk Myelodysplastic Syndromes with Unique Clinical and Biological Features and Clinical Endpoints. <i>Blood</i> , 2020, 136, 29-29.	0.6	2
45	Pomalidomide Plus Low Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World 'Powerful' Study. <i>Blood</i> , 2020, 136, 33-35.	0.6	0
46	T Cell Immunoprofiling of Patients with Relapsed and/or Refractory Myeloma Who Receive Daratumumab Monotherapy: Longitudinal Analysis during 7 Cycle Follow-up of the Rebuild Phase 2 Study. <i>Blood</i> , 2020, 136, 28-28.	0.6	1
47	Reversal of skin changes in smoldering myeloma with clinical presentation of POEMS syndrome with a lenalidomide-based regimen. <i>Annals of Hematology</i> , 2019, 98, 2625-2626.	0.8	2
48	Genomic variants in members of the Krüppel-like factor gene family are associated with disease severity and hydroxyurea treatment efficacy in β -hemoglobinopathies patients. <i>Pharmacogenomics</i> , 2019, 20, 791-801.	0.6	3
49	Azacytidine failure revisited: an appraisal based on real life data from the MDS registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS).. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019045.	0.5	5
50	A new research initiative amongst hematologists to address current worldwide health disparities in the management and treatment of Gaucher disease. <i>Molecular Genetics and Metabolism</i> , 2019, 126, S33.	0.5	0
51	Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2019, 98, 2139-2150.	0.8	39
52	A revised international prognostic score system for Waldenström's macroglobulinemia. <i>Leukemia</i> , 2019, 33, 2654-2661.	3.3	53
53	Role of Genomic Biomarkers in Increasing Fetal Hemoglobin Levels Upon Hydroxyurea Therapy and in β -Thalassemia Intermedia: A Validation Cohort Study. <i>Hemoglobin</i> , 2019, 43, 27-33.	0.4	7
54	The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registry. <i>Cancer Medicine</i> , 2019, 8, 2056-2063.	1.3	6

#	ARTICLE	IF	CITATIONS
55	Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome. <i>Annals of Hematology</i> , 2019, 98, 1383-1392.	0.8	9
56	Chronic myelomonocytic leukemia treated with 5-azacytidine – results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system. <i>Leukemia and Lymphoma</i> , 2019, 60, 1721-1730.	0.6	12
57	Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. <i>International Journal of Cancer</i> , 2019, 145, 559-568.	2.3	10
58	Evolving Treatment Trends in Relapsed/Refractory Multiple Myeloma (RRMM) in Europe from 2016 to 2018: Analysis of a Multi-National Survey. <i>Blood</i> , 2019, 134, 3115-3115.	0.6	4
59	Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group. <i>Blood</i> , 2019, 134, 844-844.	0.6	3
60	Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study). <i>Blood</i> , 2019, 134, 1837-1837.	0.6	2
61	Bone Marrow Ribonucleotide Reductase mRNA Levels and Methylation Status As a Prognostic Factor in Patients with Myelodysplastic Syndrome Treated with 5-Azacytidine. <i>Blood</i> , 2019, 134, 1721-1721.	0.6	1
62	Sickle-Cell Disease in Greece: Patient Reported Outcomes Related to Clinical Complications, Treatment Choices and Attitudes, Beliefs and Trends Affecting Potential Participation in Clinical Trials - a Greek National Multicentric Study. <i>Blood</i> , 2019, 134, 4838-4838.	0.6	2
63	Efficacy of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: An Interim Analysis of a Phase 2 Study (the DARE Study). <i>Blood</i> , 2019, 134, 1881-1881.	0.6	0
64	The Prognostic Significance of Monocytopenia in Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2019, 134, 5427-5427.	0.6	0
65	I-Care for MDS: Development of Guidelines-Based Indicators for Appropriate Care in Adult Patients with Myelodysplastic Syndromes. <i>Blood</i> , 2019, 134, 4752-4752.	0.6	0
66	Estimated Glomerular Filtration Rate Is an Independent Predictor of Outcome in High-Risk Myelodysplastic Syndrome (MDS) and Low Blast Count Acute Myeloid Leukaemia (AML) Patients Treated with Azacytidine (AZA). a Retrospective Study from the MDS Registry of the Hellenic MDS Study Group. <i>Blood</i> , 2019, 134, 5423-5423.	0.6	0
67	Molecular Mechanisms of Primary Resistance to Azacytidine in MDS/AML Patients - Data of the Hellenic MDS Study Group. <i>Blood</i> , 2019, 134, 5403-5403.	0.6	0
68	Prognostic Significance of Bone Marrow Cellularity in the Outcome of Patients with Myelodysplastic Syndromes Treated with Azacytidine: A Retrospective Analysis from the Hellenic MDS Study Group. <i>Blood</i> , 2019, 134, 5417-5417.	0.6	0
69	Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece. <i>Blood</i> , 2019, 134, 5340-5340.	0.6	1
70	Longitudinal T Cell Immunoprofiling of Patients with Relapsed and/or Refractory Myeloma Who Receive Daratumumab Monotherapy: A Subanalysis of a Phase 2 Study (the REBUILD Study). <i>Blood</i> , 2019, 134, 3167-3167.	0.6	2
71	DNA Repair Genes' Expression Abnormalities in De Novo Acute Myelogenous Leukemia (AML): Implications for Targeted Treatment. <i>Blood</i> , 2019, 134, 5176-5176.	0.6	0
72	The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacytidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group. <i>American Journal of Hematology</i> , 2018, 93, 895-901.	2.0	10

#	ARTICLE	IF	CITATIONS
73	A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin- α in anemic patients with low-risk MDS. <i>Leukemia</i> , 2018, 32, 2648-2658.	3.3	100
74	Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS. <i>Leukemia Research</i> , 2018, 67, 21-26.	0.4	4
75	Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study. <i>Leukemia</i> , 2018, 32, 1380-1392.	3.3	66
76	Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. <i>Blood Cancer Journal</i> , 2018, 8, 31.	2.8	35
77	Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 68, 203-208.	0.6	82
78	Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes. <i>Haematologica</i> , 2018, 103, 69-79.	1.7	35
79	A revised international prognostic score system for Waldenström's macroglobulinemia. <i>Annals of Oncology</i> , 2018, 29, viii359.	0.6	0
80	Impact of ZBTB7A hypomethylation and expression patterns on treatment response to hydroxyurea. <i>Human Genomics</i> , 2018, 12, 45.	1.4	10
81	Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes. <i>Blood Advances</i> , 2018, 2, 2079-2089.	2.5	18
82	Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival. <i>Annals of Hematology</i> , 2018, 97, 1671-1682.	0.8	17
83	Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group. <i>Leukemia Research</i> , 2018, 71, 55-59.	0.4	0
84	The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group. <i>Hematological Oncology</i> , 2018, 36, 693-700.	0.8	14
85	MDS Diagnosis: Many Patients May Not Require Bone Marrow Examination. <i>Blood</i> , 2018, 132, 4357-4357.	0.6	1
86	Hepatitis C Virus Infection, but Not Hepatic Iron Overload Is the Dominant Risk Factor for the Manifestation of Hepatocellular Carcinoma Among Greek Thalassemic Patients. <i>Blood</i> , 2018, 132, 2347-2347.	0.6	2
87	Second Primary Malignancies and Disease Transformation in Newly Diagnosed Symptomatic Patients with Waldenström's Macroglobulinemia: An Analysis from the Greek Myeloma Study Group. <i>Blood</i> , 2018, 132, 1978-1978.	0.6	1
88	Elevated Labile Plasma Iron (LPI) Levels in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Are Associated with Decreased Quality of Life and Reduced Survival. <i>Blood</i> , 2018, 132, 4392-4392.	0.6	0
89	Increased Age-Related B-Cells in Patients with Aplastic Anemia. <i>Blood</i> , 2018, 132, 5099-5099.	0.6	0
90	Excess Mortality in Low-Risk MDS Can be Explained By MDS and AML Related Causes of Death. <i>Blood</i> , 2018, 132, 4385-4385.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Neurological Manifestations Due to Extramedullary Hematopoiesis in Greek Patients with Thalassemia Intermedia: Not Such a Rare Clinical Finding. <i>Blood</i> , 2018, 132, 2349-2349.	0.6	0
92	Deriving Core Patient-Reported Outcomes in Patients with Myelodysplastic Syndromes – a Delphi Survey from the European-MDS Registry. <i>Blood</i> , 2018, 132, 2295-2295.	0.6	0
93	Characteristics of Long-Term Survival of Patients with MDS Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry. <i>Blood</i> , 2018, 132, 3107-3107.	0.6	0
94	Systemic Mastocytosis: Management and Outcome. Data Analysis from the Greek Registry. <i>Blood</i> , 2018, 132, 5463-5463.	0.6	0
95	Prognostic Significance of Severe Thrombocytopenia in Overall Survival of Patients with Myelodysplastic Syndromes Treated with Azacytidine. a Multicenter Study By the Hellenic MDS Study Group. <i>Blood</i> , 2018, 132, 1822-1822.	0.6	0
96	Occupational, dietary, and other risk factors for myelodysplastic syndromes in Western Greece. <i>Hematology</i> , 2017, 22, 419-429.	0.7	19
97	Poly (ADP-ribose) polymerase 1 mRNA levels strongly correlate with the prognosis of myelodysplastic syndromes. <i>Blood Cancer Journal</i> , 2017, 7, e533-e533.	2.8	12
98	Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 1753-1762.	0.6	278
99	Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance. <i>Annals of Hematology</i> , 2017, 96, 1105-1112.	0.8	11
100	A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes. <i>Leukemia</i> , 2017, 31, 1944-1950.	3.3	86
101	Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. <i>Journal of Internal Medicine</i> , 2017, 281, 284-299.	2.7	26
102	Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 241-250.	5.1	212
103	A Revised Staging System for Waldenström's Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S332-S333.	0.2	0
104	Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. <i>European Journal of Haematology</i> , 2017, 99, 409-414.	1.1	37
105	A Phase 3 Randomized Placebo (PBO)-Controlled Double-Blind Trial of Darbepoetin Alfa in Low or Intermediate-1 (INT-1) Risk Myelodysplastic Syndromes (MDS). <i>Leukemia Research</i> , 2017, 55, S29-S30.	0.4	1
106	A retrospective study of azacitidine treatment in patients with intermediate-2 or high risk myelodysplastic syndromes in a real-world clinical setting in Greece. <i>International Journal of Hematology</i> , 2017, 105, 184-195.	0.7	4
107	Whole transcriptome analysis of human erythropoietic cells during ontogenesis suggests a role of VEGFA gene as modulator of fetal hemoglobin and pharmacogenomic biomarker of treatment response to hydroxyurea in β^2 -type hemoglobinopathy patients. <i>Human Genomics</i> , 2017, 11, 24.	1.4	11
108	Immune Dysregulation in Myelodysplastic Syndromes: Pathogenetic-Pathophysiologic Aspects and Clinical Consequences. , 2016, , .		2

#	ARTICLE	IF	CITATIONS
109	Correlation of <i>SIN3A</i> genomic variants with β^2 -hemoglobinopathies disease severity and hydroxyurea treatment efficacy. <i>Pharmacogenomics</i> , 2016, 17, 1785-1793.	0.6	12
110	Genomic variants in the <i>ASS1</i> gene, involved in the nitric oxide biosynthesis and signaling pathway, predict hydroxyurea treatment efficacy in compound sickle cell disease/ β^2 -thalassemia patients. <i>Pharmacogenomics</i> , 2016, 17, 393-403.	0.6	10
111	PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy. <i>Leukemia</i> , 2016, 30, 238-242.	3.3	43
112	A Phase 3 Randomized Placebo (PBO)-Controlled Double-Blind Trial of Darbepoetin Alfa in the Treatment of Anemia in Patients with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2016, 128, 2010-2010.	0.6	3
113	Impact of Treatment with Iron Chelators in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry. <i>Blood</i> , 2016, 128, 3186-3186.	0.6	14
114	Lenalidomide, Adriamycin, and Dexamethasone (RAD) As Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Transplantation (ASCT): A Phase 2 Study from the Greek Myeloma Study Group. <i>Blood</i> , 2016, 128, 4488-4488.	0.6	0
115	Increased T Follicular Helper Cells in Patients with Aplastic Anemia. <i>Blood</i> , 2016, 128, 3907-3907.	0.6	1
116	Expression of Poly [ADP-Ribose] Polymerase 1 (PARP-1) and Uridine-Cytidine Kinase (UCK) 1 and 2 in Myelodysplastic Syndrome. <i>Blood</i> , 2016, 128, 3183-3183.	0.6	0
117	Survivorship in WM: Identification of Factors Associated with Survival of More Than a Decade and with Early WM-Related Death. <i>Blood</i> , 2016, 128, 2954-2954.	0.6	0
118	Validation of the Revised International Prognostic Scoring System in 2582 Patients with Myelodysplastic Syndrome: A Multicenter Study By the Hellenic MDS Study Group. <i>Blood</i> , 2016, 128, 2004-2004.	0.6	0
119	Real-World Data on Clinical Characteristics, Prognosis and Outcome of Primary Plasma Cell Leukemia: A Study of the Greek Myeloma Study Group in the Era of Novel Agents. <i>Blood</i> , 2016, 128, 4490-4490.	0.6	0
120	Competing risk survival analysis in patients with symptomatic Waldenstrom macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy. <i>Haematologica</i> , 2015, 100, e446-e449.	1.7	44
121	Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. <i>Blood</i> , 2015, 125, 499-503.	0.6	115
122	Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation. <i>Blood</i> , 2015, 126, 1885-1892.	0.6	76
123	Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study. <i>Blood</i> , 2015, 126, 1392-1394.	0.6	108
124	Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , 2015, 171, 239-246.	1.2	80
125	Validation of the revised international prognostic scoring system (IPSS) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. <i>British Journal of Haematology</i> , 2015, 170, 372-383.	1.2	72
126	Evaluation of a Bone Marrow Dysmyelopoiesis Immunophenotypic Index for the Diagnosis and Prognosis of Myelodysplastic Syndromes. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2015, 15, 148-161.	0.2	1

#	ARTICLE	IF	CITATIONS
127	212 TRANSFUSIONS AND PRESENCE OF RINGSIDEROBLASTS INFLUENCE HEPCIDIN AND NTBI LEVELS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) - A REPORT FROM THE EUROPEAN LEUKEMIANET MDS REGISTRY. <i>Leukemia Research</i> , 2015, 39, S106-S107.	0.4	0
128	51 PROGNOSTIC IMPACT OF TRANSFUSION INTENSITY ON SURVIVAL AND THROMBOCYTOPENIA IN NEWLY DIAGNOSED LOWER-RISK MDS PATIENTS PARTICIPATING IN THE EUROPEAN LEUKEMIANET MDS (EUMDS) REGISTRY. <i>Leukemia Research</i> , 2015, 39, S23-S24.	0.4	0
129	Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience. <i>Annals of Hematology</i> , 2015, 94, 2033-2042.	0.8	43
130	Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 372, 142-152.	13.9	1,144
131	Labile Plasma Iron (LPI) Is a Clinical Indicator of Overt Iron Overload in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry. <i>Blood</i> , 2015, 126, 2865-2865.	0.6	3
132	Prognostic Impact of Transfusions Intensity on Survival and Development of Thrombocytopenia in Newly Diagnosed Lower-Risk MDS Patients Participating in the European Leukemianet EU-MDS Registry. <i>Blood</i> , 2015, 126, 1677-1677.	0.6	0
133	Severe Impairment of Regulatory T-Cells and Th1-Lymphocyte Polarization in Patients with Gaucher Disease. <i>JIMD Reports</i> , 2014, 18, 107-115.	0.7	11
134	Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents. <i>European Journal of Haematology</i> , 2014, 92, 308-312.	1.1	31
135	Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group. <i>American Journal of Hematology</i> , 2014, 89, 145-150.	2.0	56
136	Real-world data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. <i>Annals of Hematology</i> , 2014, 93, 129-139.	0.8	38
137	Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma. <i>Leukemia</i> , 2014, 28, 2075-2079.	3.3	57
138	The Burden of Myelofibrosis In Greece. <i>Value in Health</i> , 2014, 17, A528.	0.1	0
139	Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients. <i>American Journal of Hematology</i> , 2014, 89, 803-808.	2.0	54
140	Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. <i>Annals of Oncology</i> , 2014, 25, 195-200.	0.6	126
141	The Overall Response Rate Of Azacitidine In Patients With Intermediate-2 And High Risk Myelodysplastic Syndromes: A Retrospective Chart Review Study From Greece. <i>Value in Health</i> , 2014, 17, A223-A224.	0.1	0
142	Hypercalcemia Remains an Adverse Prognostic Factor for Newly Diagnosed Patients with Symptomatic Multiple Myeloma in the Era of Novel Anti-Myeloma Therapies, Independently of Age, ISS Stage and Treatment Type: An Analysis of 2129 Patients. <i>Blood</i> , 2014, 124, 2113-2113.	0.6	3
143	Greek Registry of Myelofibrosis: Baseline Characteristics and Therapeutic Strategy. <i>Blood</i> , 2014, 124, 5557-5557.	0.6	0
144	No Survival Improvement for Central Nervous System Multiple Myeloma By the Use of Novel Anti-Myeloma Agents: The Greek Myeloma Study Group Experience. <i>Blood</i> , 2014, 124, 4752-4752.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia. <i>Blood</i> , 2014, 124, 2212-2212.	0.6	0
146	Hepcidin and GDF15 Levels during the First 2 Years Follow-up in Patients with Low and Int-1 Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry. <i>Blood</i> , 2014, 124, 3267-3267.	0.6	0
147	The incidence of myelodysplastic syndromes in Western Greece is increasing. <i>Annals of Hematology</i> , 2013, 92, 877-887.	0.8	23
148	Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. <i>Blood</i> , 2013, 122, 2943-2964.	0.6	567
149	O-027 European distribution of usage and impact on outcome for treatment with erythropoietic stimulating agents within the EUMDS lower-risk registry programme. <i>Leukemia Research</i> , 2013, 37, S21-S22.	0.4	0
150	^{99m} Tc Sestamibi as a Prognostic Factor of Response to First-Line Therapy and Outcome in Patients With Malignant Lymphoma. <i>Clinical Nuclear Medicine</i> , 2013, 38, 847-854.	0.7	2
151	IgD Myeloma: Clinical Features and Outcome In The Era Of Novel Agents. <i>Blood</i> , 2013, 122, 1935-1935.	0.6	18
152	Validation Of The Revised International Prognostic Scoring System (IPSS-R) In 1000 Newly Diagnosed MDS Patients With Low- and Intermediate-1 Risk MDS In The European Leukemianet MDS (EUMDS) Registry. <i>Blood</i> , 2013, 122, 2770-2770.	0.6	3
153	Comparison of Allogeneic Stem Cell Transplantation and Non-Transplant Approaches in Elderly Patients with Advanced Myelodysplastic Syndrome: Optimal Statistical Approaches and a Critical Appraisal of Clinical Results Using Non-Randomized Data. <i>PLoS ONE</i> , 2013, 8, e74368.	1.1	25
154	Estimated Glomerular Filtration Rate Calculated By The CKD-EPI Formula Has Improved Prognostic Ability Over MDRD Formula In Patients With Newly Diagnosed, Symptomatic, Multiple Myeloma: Analysis In 1937 Patients. <i>Blood</i> , 2013, 122, 1867-1867.	0.6	1
155	Characterization Of T Follicular Helper Cells In Patients With Low Risk Myelodysplastic Syndromes. <i>Blood</i> , 2013, 122, 4729-4729.	0.6	0
156	Preserved Levels Of Uninvolved Immunoglobulins Are Associated With Better Overall Survival In Patients With Multiple Myeloma Independently Of Disease Burden: A Role For The Immune System?. <i>Blood</i> , 2013, 122, 1866-1866.	0.6	0
157	Clinical Features, Outcome and Prognostic Factors For Survival and Evolution To Multiple Myeloma Of Solitary Plasmacytomas: A Report Of The Greek Myeloma Study Group In 97 Patients. <i>Blood</i> , 2013, 122, 3130-3130.	0.6	0
158	Rituximab Is Highly Effective In The Treatment Of Patients With Autoimmune Blood Cytopenias, Particularly When It Is Followed By a Post-Induction Consolidation / Maintenance Phase. <i>Blood</i> , 2013, 122, 3539-3539.	0.6	0
159	6-mercaptopurine influences <i>TPMT</i> gene transcription in a <i>TPMT</i> gene promoter variable number of tandem repeats-dependent manner. <i>Pharmacogenomics</i> , 2012, 13, 283-295.	0.6	21
160	Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study. <i>Leukemia</i> , 2012, 26, 1286-1292.	3.3	112
161	Effect of the gonadotropin-releasing hormone antagonist cetorelix on the prevention of chemotherapy-induced ovarian damage in women with hematological malignancy. <i>International Journal of Gynecology and Obstetrics</i> , 2012, 118, 73-74.	1.0	4
162	Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era. <i>European Journal of Haematology</i> , 2012, 89, 10-15.	1.1	28

#	ARTICLE	IF	CITATIONS
163	Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Final Analysis of a Phase II Study. <i>Blood</i> , 2012, 120, 438-438.	0.6	12
164	Significant Improvement of the Survival of Patients with Multiple Myeloma Presenting with Severe Renal Impairment After the Introduction of Novel Agents. <i>Blood</i> , 2012, 120, 948-948.	0.6	0
165	Hesk Ratio: A Complementary Tool for the Diagnosis of Myelodysplastic Syndromes and a Novel Method for Flow Cytometry Analysis. <i>Blood</i> , 2012, 120, 4946-4946.	0.6	0
166	Occurrence of Neoplastic Diseases in a Large Cohort of Thalassaemic Patients in Greece. <i>Blood</i> , 2012, 120, 3264-3264.	0.6	0
167	Overexpression of phosphorylated p27 ^{Kip1} at threonine 187 may predict outcome in aggressive B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2011, 52, 814-822.	0.6	2
168	Prognostication of the High-Risk WM Patient. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 127-129.	0.2	1
169	Effects of the gonadotropin-releasing hormone antagonist cetrorelix in the early postimplantation period on rat pregnancy. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2011, 155, 166-170.	0.5	4
170	Pathophysiology and Pharmacological Targeting of Tumor-Induced Bone Disease: Current Status and Emerging Therapeutic Interventions. <i>Current Medicinal Chemistry</i> , 2011, 18, 1584-1598.	1.2	11
171	Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis. <i>Haematologica</i> , 2011, 96, 291-297.	1.7	51
172	Increased RANKL and IL-6 levels might result in high bone turnover in a case of a CD34+/CD117+/myeloperoxidase+dim acute myeloid leukemia presenting with severe hypercalcemia and lumbar spine fractures. <i>Leukemia Research</i> , 2011, 35, e188-e189.	0.4	3
173	No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years. <i>American Journal of Hematology</i> , 2011, 86, 479-483.	2.0	43
174	Successful mobilization with plerixafor and autologous hematopoietic SCT in a patient with refractory Hodgkin's lymphoma and Gaucher disease. <i>Bone Marrow Transplantation</i> , 2011, 46, 1161-1162.	1.3	2
175	Transfusion-Dependency Is the Most Important Prognostic Factor for Survival in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European LeukemiaNet MDS Registry. <i>Blood</i> , 2011, 118, 2775-2775.	0.6	20
176	Post-Approval Safety Study (PASS) of Lenalidomide Compared with Other Treatments in Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2011, 118, 1867-1867.	0.6	0
177	Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion. <i>Haematologica</i> , 2010, 95, 406-414.	1.7	48
178	Technetium-99m depreotide imaging by single photon emission tomography/low resolution computed tomography in malignant lymphomas: comparison with gallium-67 citrate. <i>Annals of Nuclear Medicine</i> , 2010, 24, 639-647.	1.2	1
179	High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents. <i>European Journal of Haematology</i> , 2010, 85, 114-119.	1.1	113
180	Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). <i>Leukemia Research</i> , 2010, 34, 1340-1343.	0.4	56

#	ARTICLE	IF	CITATIONS
181	Physicians Poster Abstracts. Bone Marrow Transplantation, 2010, 45, S78-S327.	1.3	1
182	Disease-Management of Low- and Intermediate-1 Risk Myelodysplastic Syndromes: Report on 800 Newly Diagnosed MDS Patients From the European LeukemiaNet MDS Registry. Blood, 2010, 116, 2917-2917.	0.6	5
183	Health-Related Quality of Life In Newly Diagnosed Low Risk and Intermediate-1 Risk MDS: Report on the First 683 Patients From the European LeukemiaNet Registry. Blood, 2010, 116, 3999-3999.	0.6	1
184	Disease-Related Anemia in Chronic Lymphocytic Leukemia Is Not Due to Intrinsic Defects of Erythroid Precursors: A Possible Pathogenetic Role for Tumor Necrosis Factor-Alpha. Acta Haematologica, 2009, 121, 187-195.	0.7	25
185	P013 Hellenic national registry of myelodysplastic and bone marrow failure syndromes (EAKMYS): report of 18 months of activity. Leukemia Research, 2009, 33, S65.	0.4	0
186	P015 European LeukemiaNet registry programme for low/INT-1 IPSS score myelodysplastic syndromes. Leukemia Research, 2009, 33, S66-S67.	0.4	0
187	P027 Prognostic significance of less frequent or rare chromosome abnormalities in Greek patients with myelodysplastic syndromes. Leukemia Research, 2009, 33, S73-S74.	0.4	0
188	P028 Survival, prognostic factors, and leukemic transformation in a multicenter study of 241 patients with MDS and del(5q). Leukemia Research, 2009, 33, S74.	0.4	0
189	P060 CD34+ marrow cells from MDS patients are characterized by higher levels of intracellular reactive oxygen species and inadequate antioxidant defences. Leukemia Research, 2009, 33, S93-S94.	0.4	2
190	P063 DNA damage in peripheral blood cells of MDS patients. Leukemia Research, 2009, 33, S95-S96.	0.4	0
191	P103 Iron chelation treatment in patients with myelodysplastic syndromes (MDS): the experience of the Hellenic MDS Study Group. Leukemia Research, 2009, 33, S119-S120.	0.4	1
192	P113 Treatment with lenalidomide for patients with myelodysplastic syndromes (MDS): report of the Hellenic experience on 73 patients. A retrospective analysis of the Hellenic MDS Study Group. Leukemia Research, 2009, 33, S125.	0.4	0
193	P130 Treatment of intermediate and high risk myelodysplastic syndrome patients with azacitidine. The Hellenic experience. Leukemia Research, 2009, 33, S134-S135.	0.4	0
194	Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia, 2009, 23, 1152-1157.	3.3	176
195	The role of iron and iron chelators in zygomycosis. Clinical Microbiology and Infection, 2009, 15, 26-32.	2.8	47
196	Prognostication in Young and Old Patients with Waldenström's Macroglobulinemia: Importance of the International Prognostic Scoring System and of Serum Lactate Dehydrogenase. Clinical Lymphoma and Myeloma, 2009, 9, 50-52.	1.4	28
197	Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica, 2009, 94, 542-549.	1.7	108
198	Survival, Prognostic Factors, and Rates of Leukemic Transformation in a Multicenter Study of 303 Untreated Patients with MDS and Del(5q).. Blood, 2009, 114, 945-945.	0.6	6

#	ARTICLE	IF	CITATIONS
199	Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's Macroglobulinemia (WM) and the Importance of Serum Lactate Dehydrogenase (LDH).. Blood, 2009, 114, 2845-2845.	0.6	0
200	Tc-99m Depreotide SPECT/CT Depicts Myocardial Involvement in a Case of Thrombotic Thrombocytopenic Purpura. Clinical Nuclear Medicine, 2008, 33, 874-875.	0.7	4
201	Improved Survival of Patients with Multiple Myeloma after the Introduction of Novel Agents and the Applicability of the International Staging System (ISS) An Analysis of the Greek Myeloma Study Group (GMSG). Blood, 2008, 112, 655-655.	0.6	0
202	Primary Treatment of Waldenström Macroglobulinemia With Dexamethasone, Rituximab, and Cyclophosphamide. Journal of Clinical Oncology, 2007, 25, 3344-3349.	0.8	264
203	Renal failure in multiple myeloma: Incidence, correlations, and prognostic significance. Leukemia and Lymphoma, 2007, 48, 337-341.	0.6	186
204	Expression of the regulatory cell cycle proteins p21, p27, p14, p16, p53, mdm2, and cyclin E in bone marrow biopsies with acute myeloid leukemia. Correlation with patients' survival. Pathology Research and Practice, 2007, 203, 199-207.	1.0	27
205	P013 Chronic myelomonocytic leukemia (CMML): one disease with two phases or two different diseases?. Leukemia Research, 2007, 31, S47-S48.	0.4	0
206	P140 Factors predicting for a favorable response among patients with myelodysplastic syndromes treated with erythropoietin ± G-CSF. Leukemia Research, 2007, 31, S116-S117.	0.4	2
207	Prognostic significance of deletion of the long arm of chromosome 20 in patients with myelodysplastic syndrome (MDS): a study of the Greek MDS Study Group. European Journal of Haematology, 2007, 78, 89-90.	1.1	1
208	Symptomatic Waldenström's Macroglobulinemia (WM) in Young Patients: Disease Characteristics and Outcome.. Blood, 2007, 110, 4730-4730.	0.6	0
209	Macrofocal multiple myeloma in young patients: A distinct entity with favorable prognosis. Leukemia and Lymphoma, 2006, 47, 1553-1556.	0.6	30
210	Prognostic Value of Serum β_2 -Microglobulin in Patients with Waldenström's Macroglobulinemia Requiring Treatment. Clinical Lymphoma and Myeloma, 2006, 7, 205-209.	1.4	22
211	Dendritic cells in patients with type I Gaucher disease are decreased in number but functionally normal. Blood Cells, Molecules, and Diseases, 2006, 36, 298-307.	0.6	21
212	Increased CA-15.3 levels in the serum of patients with homozygous beta-thalassaemia and sickle cell/beta-thalassaemia. British Journal of Haematology, 2006, 133, 692-694.	1.2	9
213	Allogeneic stem cell transplantation from donors with mosaic Turner syndrome. Bone Marrow Transplantation, 2006, 38, 385-386.	1.3	7
214	Inappropriately low erythropoietin response for the degree of anemia in patients with noninsulin-dependent diabetes mellitus. Annals of Hematology, 2006, 85, 79-85.	0.8	66
215	Constitutional pericentric inversion of chromosome 9 and hematopoietic recovery after allogeneic stem cell transplantation. Annals of Hematology, 2006, 85, 611-615.	0.8	6
216	Macrophage Inflammatory Protein-1 alpha (MIP-1alpha) is over-expressed in a cohort of patients with myelodysplastic syndromes. European Journal of Haematology, 2005, 75, 85-86.	1.1	5

#	ARTICLE	IF	CITATIONS
217	Multiple myeloma in elderly patients: prognostic factors and outcome. <i>European Journal of Haematology</i> , 2005, 75, 370-375.	1.1	48
218	Non-Hodgkin's Lymphomas in Greece according to the WHO Classification of Lymphoid Neoplasms. <i>Acta Haematologica</i> , 2005, 113, 97-103.	0.7	32
219	Involvement of ERK, p38 and NF- κ B Signalling in the Maturation Defects of Monocyte Derived Dendritic Cells in Patients with Myelodysplastic Syndrome.. <i>Blood</i> , 2005, 106, 4891-4891.	0.6	1
220	Increased Serum CA-15.3 Levels in Patients with Megaloblastic Anemia due to Vitamin B ₁₂ Deficiency. <i>Oncology</i> , 2004, 67, 359-367.	0.9	19
221	Impaired generation of bone marrow CD34-derived dendritic cells with low peripheral blood subsets in patients with myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2004, 126, 806-814.	1.2	15
222	Impaired clonogenic growth of myelodysplastic bone marrow progenitors in vitro is irrelevant to their apoptotic state. <i>Leukemia Research</i> , 2004, 28, 805-812.	0.4	12
223	The International Staging System for Multiple Myeloma is Applicable in Symptomatic Waldenstrom's Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2004, 45, 1809-1813.	0.6	35
224	Primary Treatment of Waldenstrom's Macroglobulinemia (WM) with Dexamethasone, Rituximab and Cyclophosphamide.. <i>Blood</i> , 2004, 104, 752-752.	0.6	7
225	A Randomized Trial Comparing Intensified CNOP vs. CHOP in Patients with Aggressive Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2003, 44, 635-644.	0.6	9
226	Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. <i>Annals of Oncology</i> , 2003, 14, 1039-1044.	0.6	69
227	Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia. <i>Annals of Oncology</i> , 2003, 14, 1299-1305.	0.6	45
228	Relative Iron "Overload" in Offspring of Patients with Type 2 Diabetes Mellitus: A New Component in the Conundrum of Insulin Resistance Syndrome?. <i>Hormones</i> , 2003, 2, 161-168.	0.9	26
229	Determination of Plasma Cell Secreting Potential as an Index of Maturity of Myelomatous Cells and a Strong Prognostic Factor. <i>Leukemia and Lymphoma</i> , 2002, 43, 1605-1612.	0.6	8
230	Outcome of Pregnancy and Disease Course among Women with Aplastic Anemia Treated with Immunosuppression. <i>Annals of Internal Medicine</i> , 2002, 137, 164.	2.0	74
231	Ticlopidine-induced aplastic anemia: Two new case reports, review, and meta-analysis of 55 additional cases. <i>American Journal of Hematology</i> , 2002, 71, 24-32.	2.0	32
232	Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response. <i>Annals of Hematology</i> , 2002, 81, 182-186.	0.8	5
233	Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. <i>British Journal of Haematology</i> , 2002, 118, 174-180.	1.2	102
234	Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia. <i>Leukemia Research</i> , 2002, 26, 143-154.	0.4	33

#	ARTICLE	IF	CITATIONS
235	Nonmyeloablative stem cell transplantation for the treatment of cancer and life-threatening nonmalignant disorders: past accomplishments and future goals. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, S79-S84.	1.1	16
236	Impairment of erythrocyte viscoelasticity is correlated with levels of glycosylated haemoglobin in diabetic patients. <i>International Journal of Laboratory Hematology</i> , 2001, 23, 103-109.	0.2	40
237	Non Hypoxia-Related Splenic Infarct in a Patient with Sickle Cell Trait and Infectious Mononucleosis. <i>Acta Haematologica</i> , 2001, 105, 53-56.	0.7	24
238	Drug-induced Acute Malaria. <i>Scandinavian Journal of Infectious Diseases</i> , 2000, 32, 333-333.	1.5	5
239	Serum transforming growth factor- β 1 is related to the degree of immunoparesis in patients with multiple myeloma. <i>Medical Oncology</i> , 1998, 15, 124-128.	1.2	43
240	Diffuse Large Cell Lymphomas: Identification of Prognostic Factors and Validation of the International Non-Hodgkin's Lymphoma Prognostic Index. <i>Oncology</i> , 1998, 55, 405-415.	0.9	34
241	Deformability of the Erythrocyte Membrane in Patients with Myelodysplastic Syndromes. <i>Acta Haematologica</i> , 1992, 87, 169-172.	0.7	6
242	Immune function parameters at diagnosis in patients with myelodysplastic syndromes: Correlation with the FAB classification and prognosis. <i>European Journal of Haematology</i> , 1991, 47, 277-281.	1.1	36
243	Prognostic significance of immune function parameters in patients with chronic lymphocytic leukaemia. <i>European Journal of Haematology</i> , 1990, 44, 39-44.	1.1	27
244	Chronic Neutrophilic Leukemia with Dysplastic Features. <i>Acta Haematologica</i> , 1989, 82, 156-160.	0.7	29
245	Iron and Microbial Growth. , 0, , .		11